Supplementary Table 1. Data Extraction

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Study | Sample  Size | Duration of  Study | Study type | Year | Country of  study | Age of  Participants | Health  Status | setting | Dose of ARB/ARB  +HCTZ | Loss to follow up | Outcome /measurement |
| Borrios | 627 | 12 weeks | Double blinding | 2007 | Europe | 55 years | Hyperte  nsive patients | Hospital | OLM  20mg/OLM  (40Mg) +HCTZ  12.5mg | 26 | Efficacy and tolerability |
| Bonner | 1975 | 8 weeks | Double  blinding | 2008 | Europe | 55 | Hyperte  Nsive  patients | Hospital | CAN 32m/CAN32  Mg+HCTZ12.5mg | 57 | Efficacy and tolerability |
| Gleim | 292 | 10 weeks | Double  blinding | 2006 | Europe | 18 years above | Hypertensive  Patients | Hospital | LST 100mg/LST 100mg+  HCTZ 12.gm | 5 | Efficacy and tolerability |
| Makita | 64 | 12  Weeks | Double  blinding | 2009 | Japan | 18 years  Above | Hypertensive  patients | Hospital | TMSTN 40mg/  TMSTN40mg+HCTZ  12.5mg | 36 | Efficacy and tolerability |
| Rump | 698 | 12weeks | Double  blinding | 2011 | Europe | 18 years above | Hypertensive  patients | Hospital | OLM 40mg/OLM40mg+  HCTZ 25mg | 25 | Efficacy and tolerability |
| Toh | 200 | 12weeks | Double  blinding | 2012 | Japanese | 30 years above | Hypertensive  patients | Hospital | LZTN 50mg/LZTN 50  mg+HCTZN 12.5mg | 7 | Efficacy and tolerability |
| Toumileko | 3802 | 12 weeks | Double  blinding | 2008 | Japanese | 18 years above | Hypertensive  Patients | Hospital | VAL320mg/VAL320mg+  HCTZ12.5mg | 123 | Efficacy and |